The WWOX gene encodes a candidate tumor suppressor protein (WWOX) implicated in a variety of human diseases such as cancer. To better understand the molecular mechanisms of WWOX action, we investigated novel partners of this protein. Using the two-hybrid system and a coimmunoprecipitation assay, we observed a physical association between WWOX and the Dishevelled protein (Dvl) family signaling elements involved in the Wnt/b-catenin pathway. We found that enforced WWOX expression inhibited, and inhibition of endogenous WWOX expression stimulated the transcriptional activity of the Wnt/b-catenin pathway. Inhibition of endogenous WWOX expression also enhanced the effect of Wnt-3a on b-catenin stability. Moreover, we observed the sequestration of Dvl-2 wild type and Dvl-2NESm, a mutated form of Dvl-2 predominantly localized in the nucleus, in the cytoplasm compartment by WWOX. Our results indicate that WWOX is a novel inhibitor of the Wnt/b-catenin pathway. WWOX would act, at least in part, by preventing the nuclear import of the Dvl proteins.
Introduction
The WW domain-containing oxidoreductase gene (WWOX), located at 16q23.3-24.1, encompasses the common fragile site, FRA16D (Bednarek et al., 2000; Ried et al., 2000; Chang et al., 2001) . The 16q23.3-24.1 region is a frequent target of loss of heterozygosity in various carcinomas (Ludes-Meyers et al., 2003) . Homozygous deletion of WWOX exons has been found in different cancer cell lines Paige et al., 2000 Paige et al., , 2001 , and hypermethylation of the WWOX promoter has been detected in both cancer cell lines and primary tumors (Ishii et al., 2003; Kuroki et al., 2004; Iliopoulos et al., 2005) . The expression of WWOX is reduced or lost in many different cancers (Aqeilan et al., 2007c) . Notably, it has been established that WWOX is inactivated in invasive breast carcinoma (Guler et al., 2004 Chang et al., 2005; Nunez et al., 2005; Wang et al., 2009) . The decrease of WWOX expression is frequently associated with a worse clinical outcome for patients (Pluciennik et al., 2006; Hezova and Ehrmann JKolar 2007; Aqeilan et al., 2007a) . Several tumor types, such as human breast tumors, overexpress aberrant transcripts (Driouch et al., 2002; Ludes-Meyers et al., 2003) . Moreover, WWOX has the capacity to function as a tumor suppressor gene both in vitro and in vivo (Bednarek et al., 2001; Kuroki et al., 2004; Fabbri et al., 2005; Iliopoulos et al., 2007; LudesMeyers et al., 2007; Qin et al., 2007; Aqeilan et al., 2007b Aqeilan et al., , 2007c . Together, these findings suggest that WWOX is a tumor suppressor gene.
WWOX encodes a 46-kDa protein consisting of two N-terminal WW domains and a C-terminal short-chain dehydrogenase/reductase (SDR) domain (Bednarek et al., 2000; Ried et al., 2000) . The WW domain is characterized by interaction with a proline-containing ligand and mediates protein-protein interactions (Ludes-Meyers et al., 2004) . The SDR domain is shared by steroid-hormone-metabolizing enzymes. WWOX seems to be able to induce apoptosis both in the nuclear and in the cytoplasmic compartments. WWOX would therefore inhibit tumor progression by facilitating cell death.
Mammalian Dishevelled proteins (Dvls) form a family of three members (Dvl-1, Dvl-2 and Dvl-3) sharing three conserved domains termed DIX, PDZ and DEP (Wharton, 2003) . Dvls play a key role in the three different pathways activated on Wnt receptor activation: the canonical Wnt/b-catenin pathway, the planar cell polarity pathway and the Wnt/Ca 2 þ pathway (Kikuchi et al., 2006) . Wnt proteins constitute a large family of cysteine-rich secreted ligands that play pivotal roles in embryonic development and also control homeostatic self-renewal in a number of adult tissues (Clevers, 2006) .
The Wnt/b-catenin pathway is specifically activated by several Wnts, including Wnt-1, -3a, -8 and -8b. Aberrant activation of this pathway plays an important role in the development of many human cancer types (Clevers, 2006; Kikuchi et al., 2006) . Wnt initiates signaling events by binding to two receptor molecules: Frizzled proteins and lipoprotein receptor-related proteins 5 and 6 (LRP5/6). In the absence of Wnt, cytoplasmic b-catenin binds a multiprotein complex (b-catenin-degradation complex) composed notably of the glycogen synthase kinase b, Axin, Dvl, Frat, casein kinase 1e and adenomatous polyposis coli. In this complex, b-catenin is phosphorylated by glycogen synthase kinase 3b. This phosphorylation induces the ubiquitination and thus the degradation of b-catenin by the 26S proteasome. Wnt binding to its receptor induces the activity of Dvl proteins, which in turn inhibit bcatenin phosphorylation by glycogen synthase kinase 3b and thereby the accumulation of b-catenin in the cytoplasm and nucleus (Yokoyama and Yin DMalbon 2007) . In the nucleus, b-catenin binds to proteins of the T-cell factor (TCF)/lymphoid enhancer factor-1 family and stimulates TCF/lymphoid enhancer factor-1-dependent transcription of Wnt target genes.
Here, we report evidence that WWOX interacts with the three members of the Dvl family. This finding led us to study the role of WWOX in the modulation of the Wnt/b-catenin pathway.
Results

WWOX interacts with Dvl-2
To gain insight into the molecular action of WWOX, we used a yeast two-hybrid screen to identify novel partners of this protein. As bait, we used FORIII, a WWOX isoform, possessing the WW domains required for protein-protein interactions and a truncated SDR domain ( Figure 1a ). Dvl-2 is one of the novel FORIII interactors isolated in our yeast two-hybrid system (data not shown). To confirm the ability of FORIII and Dvl-2 to form a complex, we transfected 293 cells with 3xflag-FORIII and/or HA-Dvl-2 plasmid(s). We then immunoprecipitated the cell extracts with anti-HA and immunoblotted the immunoprecipitates with anti-flag to determine the presence of 3xflag-FORIII. We detected 3xflag-FORIII in the immunoprecipitate of cells expressing both 3xflag-FORIII and HA-Dvl-2, but not of cells expressing either 3xflag-FORIII or HA-Dvl-2 alone (Figure 1b ). In the same way, we analysed the ability of wild-type WWOX to associate with Dvl-2. We also detected 3xflag-WWOX in the HA-immunoprecipitate from cells expressing both 3xflag-WWOX and HA-Dvl-2, but not in negative control transfections ( Figure 1c) . We detected the same WWOX-Dvl-2 interaction in the absence or in the presence of Wnt3a, suggesting that the Wnt/b-catenin pathway may not regulate the interaction (Figure 1d ). Taken together, these results indicate that WWOX interacts with Dvl-2 in vivo.
We immunoprecipitated 293 cell extracts either with no specific IgG or with an antibody against Dvl-2, and then immunoblotted the immunoprecipitates with an anti-WWOX antibody (Figure 1e ). In this experiment, WWOX specifically coprecipitated with Dvl-2 indicating that WWOX and Dvl-2 associate at endogenous levels of expression (Figure 1f) .
We also found that WWOX and FORIII associated with Dvl-1 and Dvl-3, the other two members of the Dvl family, in a coimmunoprecipitation assay (Figures 1g  and h , and data not shown). Therefore, WWOX has the ability to interact with all three members of the Dvl family. This finding is consistent with the fact that Dvl proteins possess very closely related domains.
Binding domains
To identify the binding domain of Dvl-2 for WWOX, we generated expression vectors coding for different regions of Dvl-2 and tested their abilities to complex with WWOX in a coimmunoprecipitation assay (Figures 2a  and b ). Dvl-2 (2-231) containing the DIX domain did not interact with WWOX. Dvl-2 (232-739) containing the PDZ and the DEP domains, and Dvl-2 (2-409) containing the DIX and PDZ domains associated with WWOX. These results suggest that the region containing residues 231-409 of Dvl-2 is mainly responsible for the Dvl-2-WWOX interaction.
In the same way, we also searched for the binding domain of WWOX for Dvl-2 (Figures 2c and d) . Consistent with the observation that FORIII interacts with Dvl-2, we found that the WW domains associated with this protein. Moreover, we also found that the SDR domain interacted with Dvl-2. These results indicate that the complete binding domain of WWOX for Dvl-2 contains the WW and at least part of the SDR domains.
WWOX inhibits the Wnt/b-catenin pathway transcriptional activity Dvl proteins are key components of the Wnt/b-catenin pathway. Our finding that WWOX interacts with these proteins therefore raises the possibility that WWOX acts as a regulator of this pathway. To test this, we examined the effect of WWOX on the transcriptional activities of Dvl proteins and Wnt-3a ligand in 293 cells. We carried out luciferase assays with the reporter plasmid TOPflash, which contains six TCF-binding elements. Overexpression of Dvl-2 enhanced luciferase activity by twofold, and ectopically expressed WWOX inhibited this Dvl-2-dependent activity in a dose-dependent manner (Figure 3a) . However, FORIII did not affect Dvl-2 transcriptional activity (Figure 3b ). With the reporter plasmid FOPflash containing mutated TCFbinding sites, we found that the observed effects of Dvl-2 and WWOX on TOPflash were strictly dependent on TCF-binding sites (data not shown). Ectopically expressed WWOX, but not FORIII, inhibited both Dvl-1 and Dvl-3 transcriptional activities too (Figures 3c  and d , and data not shown). Therefore, WWOX, but not FORIII, inhibits the TCF-dependent transcriptional activity of all three members of the Dvl family.
WWOX overexpression also inhibited the positive effect of Wnt-3a on TCF transcriptional activity in a dose-dependent manner (Figure 3e ). The SDR domain Functional interaction between WWOX and Wnt pathway N Bouteille et al (Polakis, 2000) , we also determined the effect of WWOX on Wnt-3a-induced transcriptional activity in a luciferase assay using the natural cyclin D1 promoter ligated to a luciferase gene (D1-Luc/D1D-848pXP2) (Herber et al., 1994) . WWOX overexpression inhibited the positive effect of Wnt-3a and of Dvl-2 on cyclin D1 promoter activity in a dose-dependent manner ( Figure 3g and data not shown).
We also observed that the ectopic expression of WWOX inhibited the TCF-dependent transcriptional activity of Dvl-1 in two human mammary carcinoma cell lines, MCF-7 and BT-474 (Figures 3h and i) . These results indicate that WWOX is able to inhibit the Wnt/ b-catenin pathway in different cancer cell types, notably in breast cancer cells.
Importantly, we found that knockdown of endogenous WWOX in 293 cells by a WWOX-specific small interfering RNA (siRNA) resulted in an increase in Wnt-3a-stimulated TOPflash activity (Figure 4) .
Taken together, these results indicate that WWOX is a novel negative regulator of the Wnt/b-catenin pathway, and that the SDR domain is essential and sufficient for this inhibitory effect.
Knockdown of endogenous WWOX expression enhances the effect of Wnt-3a on b-catenin stability In the Wnt/b-catenin pathway, Dvl proteins transmit the positive effect of Wnt on b-catenin stability (Kikuchi et al., 2006) . We determined the effect of siRNA WWOX on the endogenous b-catenin expression induced by Wnt-3a. We observed that knockdown of WWOX in 293 cells by a WWOX-specific siRNA resulted in an increase in Wnt-3a-induced b-catenin stability ( Figure 5 ). The quantification of the b-catenin expression indicates that WWOX siRNA elevated the basal level of this expression. This result is in agreement with our observation that WWOX siRNA elevated the basal level of the TCF-dependent transcriptional activity (Figure 4) . Our results therefore support the idea that WWOX inhibits the transcriptional activity of the Wnt/ b-catenin pathway by binding and inhibiting Dvl proteins.
WWOX does not affect Wnt-3a-induced Dvl-2 and LRP6 phosphorylation, and the expression and stability of Dvl-2 We then searched for the molecular mechanism by which WWOX inhibits the Wnt/b-catenin pathway. Several works indicate that Wnt-induced phosphorylation of Dvl (p-Dvl) and LRP6 at Ser 1490 (p-LRP6 (S1490)) initiates the Wnt/b-catenin pathway; moreover, Dvl is an important component that controls Wnt-induced LRP6 phosphorylation at Ser 1490 (Hino et al., 2003; Cong and Schweizer LVarmus 2004; Davidson et al., 2005; Zeng et al., 2005 Zeng et al., , 2008 Klimowski et al., 2006; Bilic et al., 2007) . Through its binding to Dvl, WWOX could repress Wnt-induced Dvl and/or LRP6 phosphorylation, thereby inhibiting the Wnt/b-catenin pathway activity. To verify these possibilities, we examined the effect of siRNA WWOX on the Wnt-3a-induced Dvl-2 and LRP6 phosphorylation ( Figure 5 ). Wnt-3a caused a weak phosphorylation of Dvl-2, which is monitored by a decrease in the electrophoretic mobility of p-Dvl-2 (Gonzalez- Sancho et al., 2004) . Wnt-3a also led to phosphorylation of LRP6 at Ser 1490 . We found that the depletion of endogenous WWOX did not enhance the ability of Wnt-3a to phosphorylate Dvl-2 or LRP6. Furthermore, we observed that knockdown of WWOX did not change the endogenous expression of Dvl-2 ( Figure 5 ) and that overexpression of WWOX did not affect the ectopic expression of Dvl-2 ( Figure 6 ).
Taken together, these results suggest that WWOX does not inhibit the Wnt/b-catenin pathway by affecting either Wnt-induced Dvl-2 and LRP6 phosphorylation or expression/stability of Dvl-2. Functional interaction between WWOX and Wnt pathway N Bouteille et al WWOX does not inhibit the interaction of Dvl-2 with the b-catenin-degradation complex In the b-catenin-degradation complex, Dvl-2 binds directly to Axin. This interaction seems to be crucial for Dvl-2 to inhibit glycogen synthase kinase 3b-dependent degradation of b-catenin (Kishida et al., 1999 Smalley et al., 1999; Kadoya et al., 2000; Hino et al., 2001) . WWOX would therefore inhibit the function of Dvl-2 in the Wnt/b-catenin pathway by disrupting Dvl-2-Axin association. To test this, we examined whether WWOX inhibits the binding of Dvl-2 to Axin in intact cells. myc-Axin, 3xflag-Dvl-2 and HIS-WWOX were coexpressed in 293 cells (Figure 7) . When the expression levels of HIS-WWOX increased, the amounts of 3xflag-Dvl-2 complexed with myc-Axin did not change. We also found that WWOX did not affect the ability of Dvl-2 to form complexes with Frat and casein kinase 1e (data not shown). These results suggest strongly that WWOX does not inhibit the Wnt/ b-catenin pathway by disrupting the interaction of Dvl-2 with the b-catenin-degradation complex. (Aqeilan et al., 2004a (Aqeilan et al., , 2004b Gaudio et al., 2006) . These results and ours therefore raise the possibility that WWOX would inhibit the transcriptional activity of the Wnt/b-catenin signaling pathway by preventing the entry of Dvl into the nucleus. To test this hypothesis, we first examined the effect of WWOX on the subcellular localization of Dvl-2 by immunofluorescence experiments in MCF-7 cells. When green fluorescent protein (GFP)-WWOX was expressed alone, it was distributed extensively in the cytoplasm in distinct perinuclear particles, and 3xflag-Dvl-2 expressed alone was observed to be localized mainly throughout the cytoplasm, in keeping with earlier reports (Lee and Ishimoto AYanagawa 1999; Bednarek et al., 2001) (Figures 8a and b) . The nuclear Figure 4 The siRNA WWOX stimulates the transcriptional activity of Wnt-3a. A total of 293 cells were transfected with siRNA control or siRNA WWOX. Forty-eight hours later, cells were transfected once again with the siRNA and also with pRL-TK Renilla and TOPflash reporter constructs. Thirty hours later, cells were treated for 16 h with (crossed bar) or without (white bar) Wnt3a-conditioned medium. Cell extracts were then prepared and luciferase activities quantified. Firefly luciferase activity was normalized to Renilla luciferase activity and expressed as mean±s.d. of triplicates from a representative experiment. Cell extracts were also examined by immunoblotting with anti-WWOX and anti-GAPDH (loading control) antibodies.
Figure 5
Inhibition of endogenous WWOX expression enhances the positive effect of Wnt-3a on b-catenin stability, but not on Dvl-2 and LRP6 phosphorylation. A total of 293 cells were transfected with siRNA control or siRNA WWOX. Forty-eight hours later, cells were transfected once again with the siRNA. Thirty hours later, cells were treated for 16 h with or without Wnt-3a-conditioned medium. Cell extracts were then prepared and examined by immunoblotting with b-catenin, WWOX, LRP6, p-LRP6(S1490), Dvl-2 and GAPDH (loading control) antibodies.
Functional interaction between WWOX and Wnt pathway N Bouteille et al
Dvl-2 level at steady state is low because of a highly efficient nuclear export (Itoh et al., 2005) . In cells expressing both GFP-WWOX and 3xflag-Dvl-2, the two exogenous proteins colocalized in the cytoplasm concentrated in distinct particles (Figure 8c ). More than 90% of transfected cells showed this colocalization. Moreover, it has recently been reported that Xenopus Dvl (Xdsh) accumulates in cell nuclei when the specific nuclear-export signal (NES) in Xdsh is disrupted by mutagenesis (Itoh et al., 2005) . To test our hypothesis according to which WWOX sequesters Dvl-2 in the cytoplasm, we determined the effect of WWOX on the subcellular localization of Dvl-2 with a mutated NES. When leucines 519 and 521 located in the NES of mouse Dvl-2 were substituted with alanines, the mutated Dvl-2, Dvl-2NESm, was localized predominantly in the nucleus as expected (Figure 8d ) By contrast, in cells cotransfected with GFP-WWOX and Dvl-2NESm, 50% of cells showed cytoplasmic staining of Dvl-2NESm, suggesting that WWOX prevents the nuclear import of Dvl-2 (Figure 8e ). We examined the transfected cells by transmitted light image but did not detect any unwell cells (data not shown); moreover, the nuclei looked normal (Figure 8 ). The WWOX/Dvl-2 complexes were localized in the cytoplasm all around the nucleus in the majority of the cotransfected MCF-7 cells. We therefore excluded the possibility that the proteins were retained in the endoplasmic reticulum when coexpressed. We have obtained similar results with 293 and COS-7 cells.
Taken together, these results indicate that WWOX is a novel inhibitor of the Wnt/b-catenin pathway. The colocalization of WWOX with Dvl-2 wild type or Dvl2NESm in the cytoplasmic compartment suggests that WWOX would act, at least in part, by sequestering Dvl proteins in the cytoplasmic compartment, thereby inhibiting their function in b-catenin stabilization.
Discussion
To unravel the molecular function of WWOX, we used a yeast two-hybrid system and coimmunoprecipitation assay to identify novel partners of this tumor suppressor protein. We found that WWOX interacts with all three members of the Dvl family. As these proteins are key mediators of the Wnt/b-catenin pathway (Kikuchi et al., 2006) , we studied the modulatory effect of WWOX on this pathway. We obtained evidence that WWOX is a novel negative regulator of the Wnt/b-catenin pathway.
Recently, it has been shown that Dvl proteins shuttle between the cytoplasm and the nucleus, and that their nuclear localizations are crucial for their functions in the Wnt/b-catenin pathway (Itoh et al., 2005; Yokoyama and Yin DMalbon 2007; Gan et al., 2008) . Itoh et al. showed notably that the nuclear localization of Xenopus Dvl is essential for its ability to stabilize b-catenin (Itoh et al., 2005; Gan et al., 2008) . Here, we observe the colocalization of WWOX with Dvl-2 wild type or Dvl2NESm (a mutated form of Dvl-2 predominantly localized in the nucleus) in the cytoplasmic compartment (Figure 8) . Therefore, we propose that WWOX inhibits the transcriptional activity of the Wnt/b-catenin pathway by preventing the nuclear import of the Dvl proteins, thereby inhibiting their positive effect on b-catenin stabilization. Our observation that the inhibition of endogenous WWOX expression enhances the effect of Wnt-3a on b-catenin stability supports this hypothesis. WWOX has earlier been shown to associate with p73, AP2-g, c-Jun and ErbB-4 in the cytoplasm and prevents their translocation into the nucleus, thereby inhibiting their transcriptional activity (Aqeilan et al., 2004a (Aqeilan et al., , 2004b Gaudio et al., 2006) . The sequestration of protein in the perinuclear compartment by WWOX seems, therefore, to be an important mechanism antagonizing the function of various proteins involved in the modulation of transcription, including Dvl proteins, in this study.
The results of Itoh et al., 2005 and ours indicate that Dvl proteins have to enter into the nucleus to stabilize b-catenin. One explanation of these results is that b-catenin degradation may occur in the nucleus and that nuclear Dvl proteins inhibit this degradation. Consistent with this hypothesis, the number of components of the b-catenin-degradation complex (adenomatous polyposis coli, Axin, etc.) also seems to shuttle between the cytoplasm and the nucleus (Willert K Jones 2006) . Alternatively, nuclear Dvl proteins may participate in the sequestration of b-catenin in the nucleus, thereby preventing its cytoplasmic degradation. 
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The FORIII transcript sequence predicts a protein possessing two WW domains and a truncated SDR domain. FORIII may thus be able to bind proteins that recognize WWOX WW domains, but not be able to carry out the enzymatic function of WWOX. Consequently, FORIII would act as a competitor of WWOX.
Figure 8 WWOX sequesters Dvl-2 in the cytoplasmic compartment. MCF-7 cells were transfected with GFP-WWOX (Green) (a, c and e), 3xflag-Dvl-2 (red) (b and c) and 3xflag-Dvl2NESm (red) (d and e) plasmids as indicated. The cells were then immunostained with anti-flag antibody, followed by Texas Red-conjugated secondary antibody and the nucleus was stained with DAPI. The nuclear GFP-WWOX, 3xflag-Dvl-2 and 3xflag-Dvl-2NESm expressions were visualized by fluorescence microscopy and the images were overlaid. 3xflag-Dvl-2 and GFP-WWOX colocalization appears in yellow in the cytoplasmic compartment.
Supporting this idea, overexpression of FORIII both prevents the interaction of WWOX with Dvl-2 and inhibits the effect of WWOX on Wnt-3a-dependent transcriptional activity (Figure 3e and data not shown).
If FORIII is indeed a competitor for WWOX, its overexpression could facilitate tumor progression by inhibiting the negative effect of WWOX on tumor growth. This is supported by reports that various WWOX transcripts lacking exons coding for the SDR domain are expressed only in cancers, or are overexpressed in cancers. Moreover, truncated WWOX proteins have been observed in hematopoietic malignancies (Ishii et al., 2003) . However, several reports show that truncated WWOX proteins are absent, despite the presence of the corresponding aberrant WWOX transcripts, in oral squamous cell carcinoma and in a variety of cancer cell lines (Watanabe et al., 2003; Pimenta et al., 2006) . This absence could be explained by the rapid degradation of truncated WWOX proteins through the proteasomal machinery (Watanabe et al., 2003) . Furthermore, we did not detect endogenous FORIII in 293 cells or in several breast cancer cell lines with our anti-WWOX antibody ( Figure 1e and data not shown), and aberrant WWOX transcripts may thus facilitate the progression of only certain tumors.
Mutations at various points of the Wnt/b-catenin pathway have been found to lead to malignant transformation of a wide variety of human tissues (Polakis, 2000; Brown, 2001) . In colon cancer, for example, 85% of tumors have loss-of-function mutations in APC, resulting in elevated b-catenin protein levels and subsequent TCF/lymphoid enhancer factor-1-b-catenin transcriptional activity. High b-catenin transcriptional activity has also been reported in 60% of human breast tumors and has been found to correlate with poor patient outcome (Lin et al., 2000) . The genetic events leading to high b-catenin activity in breast cancer have not yet been elucidated. We hypothesized that the lack of WWOX expression, which is frequent in breast cancer tissues (Driouch et al., 2002; Guler et al., 2004 Guler et al., , 2005 Chang et al., 2005) , might constitutively stimulate the Wnt/b-catenin pathway and thereby contribute to enhancing tumor growth. Our observation that knockdown of WWOX enhances Wnt-3a transcriptional activity, as well as that WWOX overexpression inhibits Dvl-1 transcriptional activity in MCF-7 and BT474 cells, supports this hypothesis.
Materials and methods
DNA constructs
FORIII and WWOX cDNAs were obtained by reverse transcriptase PCR of total RNA from breast cancer cell line, SKBR3, (for FORIII) and human thymus (Clontech, Palo Alto, CA, USA) (for WWOX). The cDNAs were cloned into pEGFP-C1 (Clontech) (for GFP-WWOX), pCMV-hemagglutinin (HA) (BD Bioscience Clontech, Palo Alto, CA) (for HA-WWOX), p3xflag-CMV-7.1 (Sigma, St Louis, MO, USA) (for 3xflag-WWOX and 3xflag-FORIII) and pcDNA3.1/HIS (Invitrogen, Carlsbad, CA, USA) (for HIS-WWOX) by using standard protocols. 3xflag-Dvl2, 3xflag-Dvl2 (2-231), 3xflag-Dvl2 (232-736), 3xflag-Dvl2 (2-409), HIS-WWOX (54-104), HIS-WWOX (1-104), HIS-WWOX (105-414) and HIS-WWOX (54-414) plasmids were constructed by inserting the appropriate cDNA fragments generated by PCR into p3xflag-CMV-7.1 or pcDNA3.1/HIS vector. All constructs were verified by DNA sequencing.
To generate Dvl-2NESm, site-directed mutagenesis was used to modify the NES motif of mouse Dvl-2 by using the QuickChange kit (Stratagene, La Jolla, CA, USA). The leucines 519 and 521 located in the NES of Dvl-2 were mutated to alanines.
Yeast Two-Hybrid Cloning and Analysis FORIII cDNA was cloned into plasmid pB27 derived from the original plasmid pBTM116 (Vojtek ABHollenberg 1995) . Random-primed cDNA libraries from human placenta poly(A þ ) RNA were constructed into plasmid pP6 derived from the original plasmid pGADGH (Barel, 1993) . The libraries were transformed into yeast strain Y187, and ten million independent yeast colonies were collected, pooled and stored at -80 1C as equivalent aliquot fractions of the same library. The mating protocol has been described elsewhere (Rain et al., 2001) . Each screen was carried out to ensure that a minimum of 50 million interactions was tested. The prey fragments of the positive clones were amplified by PCR and sequenced at their 5 0 and 3 0 junctions on a PE3700 Sequencer (Applied Biosystems, Foster City, CA, USA). The resulting sequences were used to identify the corresponding gene in the GenBank database (NCBI, Bethesda, MD, USA) with a fully automated procedure.
Cell culture and Wnt-3a conditioned medium Human embryonic kidney 293 cells, human mammary carcinoma cell line, BT-474, and mouse fibroblast L cells were maintained in Dulbecco's modified Eagle's medium. Monkey African green kidney COS-7 cells and human mammary carcinoma cell line, MCF-7, were cultured in minimum essential medium. The Dulbecco's modified Eagle's medium and minimum essential medium were supplemented with 10% fetal bovine serum and antibiotics (penicillin 50 mg/ml, streptomycin 50 mg/ml and neomycin 100 mg/ml). All cell lines were grown at 37 1C in a humidified atmosphere of 5% (v/v) CO 2 in air. To prepare a conditioned medium containing Wnt-3a (Wnt-3a-CM), Wnt-3a-producing L cells (Shibamoto et al., 1998) seeded at a density of 10 6 cells in 94-mm-diameter dishes containing 10 ml of culture medium were cultured for 4 days. The conditioned medium was then centrifuged at 1000 g for 10 min, filtered through a nitrocellulose membrane and diluted fourfold (Figures 3 and 5) or sixfold (Figure 4 ) in fresh culture medium. As a negative control, conditioned medium from L cells that had been transfected with the empty vector, pGKneo, was prepared in the same way (Shibamoto et al., 1998) .
Antibodies
The following antibodies were used in this study: WWOX produced by inoculating rabbits with the entire human protein, HA (Eurogentec, Lie`ge, Belgium); flag (Sigma); His, GAPDH (glyceraldehyde-3-phosphate dehydrogenase), b-catenin (Santa Cruz Biotechnology, Santa Cruz, CA, USA); myc (BD Bioscience Clontech); Dvl-2, LRP6 and p-LRP6 (S1490) (Cell Signaling Technology, Danvers, MA, USA).
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Reporter assays
Cells were transfected with the TOPflash (Upstate, NY, USA), FOPflash (Upstate), D1-Luc/D1Ä -848pXP2 and pRL-TK Renilla (Stratagene) reporter constructs and expression vectors, as indicated by using the Fugene 6 method (Roche, Nutley, USA). Firefly and Renilla luciferase activities were measured with a commercial kit (Dual-Luciferase Assay System, Promega, Madison, WI, USA).
siRNA experiments siRNA control (Catalog no.: 1027281) and siRNA WWOX (Catalog no.: SI02777775) were purchased from Qiagen (Valencia, CA, USA). Cells were transfected with siRNA, or with siRNA, pRL-TK Renilla and TOPflash reporter constructs as indicated using HiPerfect transfection Reagent (Qiagen) according to the manufacturer's instructions.
Coimmunoprecipitation and western blotting The methods are described in detail elsewhere (Lallemand et al., 2005) . Aliquots containing identical b-galactosidase activity were used for each coimmunoprecipitation experiment. For endogenous WWOX-Dvl-2 complex, cell extracts containing 700 mg of total protein were subjected to direct immunoprecipitation with anti-Dvl2 antibody (Santa Cruz Biotechnology). Endogenous WWOX and Dvl2 were detected by immunoblotted cell extracts containing 30 mg of total protein with appropriate antibodies. Quantifications of western blot were carried out using software BIO-1D from Vilber Lourmat (Marne la valle´e, France).
Immunofluorescence Cells were transfected with GFP-WWOX and 3xflag-Dvl-2 plasmids as indicated. Forty-eight hours later, cells were fixed for 10 min with phosphate-buffered saline containing 4% paraformaldehyde and permeabilized for 10 min with phosphate-buffered saline plus 0.1% Triton X-100. Cells were then incubated with phosphate-buffered saline containing 5% goat serum and mouse anti-flag antibody (Sigma) for 1 h followed by anti-mouse-IgG Texas Red-conjugated (Santa Cruz Biotechnology) for 1 h. Cells were then stained with DAPI (4',6-diamidino-2-phenylindole) (1 mg/ml) and examined with a fluorescence microscope (Axiovert 200 m, using X40/1.2 c-apochromat length, LSM 510 confocal microscope (Zeiss, Jena, Germany)).
